Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
about
Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation.The effectiveness of tacrolimus and minidose methotrexate in the prevention of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in children: a single-center study in KoreaFactors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantationPreparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles.Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part IReduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation.Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT.High on Cannabis and Calcineurin Inhibitors: A Word of Warning in an Era of Legalized Marijuana.Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring.Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients.Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers.Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation.Practical considerations in the use of intravenous tacrolimus in hematopoietic stem cell transplantation patients.
P2860
Q34046207-90561106-F88F-4FDE-9527-8A3CF173929BQ36074018-29ED4BB4-C9D6-4E7F-896C-2CB86CB662A0Q36418533-C0E1CE6C-9BBB-4191-A1FA-86D3D99FEB83Q36617869-095C851C-8798-4AFF-A271-ECE21947AAA9Q36777599-F9DE5CCA-E0CA-46C5-8D24-8B8EA556C8AAQ38202155-143468C3-B682-42AB-A113-F809D77EA90AQ39811655-3632071A-9BE5-41C9-8C61-16A4309A887BQ40361644-5FBB8943-E8F0-4EFD-9614-7FB82E768DEFQ41434713-8C80A96A-1C45-4923-85DA-919C396EDF80Q43228483-4C6282E4-CFD4-46DE-BDB8-373910BEAB72Q43848092-5757796E-A96C-4FC6-AF74-06BC840D5D3DQ44074090-DBB31D30-5C19-45E4-831C-9C6A69E0EA2BQ44791854-9AF29A19-A227-4485-B589-B7CD27637C65Q45169488-23D18CC2-9F70-4E2C-BF96-47F94DFCFF54Q49074524-07359E5A-3716-4C7D-B2BD-EF3361C6C92C
P2860
Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
@ast
Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
@en
type
label
Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
@ast
Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
@en
prefLabel
Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
@ast
Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
@en
P2093
P356
P1476
Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
@en
P2093
P2888
P304
P356
10.1038/SJ.BMT.1702032
P407
P577
1999-11-01T00:00:00Z
P5875
P6179
1002032194